Antiretroviral resource allocation for HIV prevention

AIDS

Volumn 27, Issue 6, 2013, Pages 863-865

  Singh, Jerome Amir ^a,b,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiretroviral drugs; HIV; Prevention; Treatment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONDOM; COUNSELING; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN RIGHTS; JURISPRUDENCE; MEDICAL ETHICS; PRIORITY JOURNAL; SCALE UP; SEROLOGY; SOUTH AFRICA; SUSTAINABLE DEVELOPMENT; TREATMENT INDICATION; UNITED STATES; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; RESOURCE ALLOCATION;

EID: 84876352601     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835f2b30     Document Type: Article

References (12)

1. Miele PS. NDA 21-752 S-030. Truvada (emtricitabine-tenofovir disoproxil fumarate) preexposure prophylaxis (PrEP) Indication for prevention of sexually acquired HIV-1. Antiviral Drugs Advisory Committee Meeting. 10 May 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM305777.pdf.
2. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 16 July 2012. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
3. WHO (2012). Guidance on oral preexposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. Recommendations for use in the context of demonstration projects. http://www.who.int/hiv/pub/guidance-prep/en/index.html.
4. Abdool-Karim SS. CAPRISA 008 trial receives go-ahead. http://www.caprisa.org/SitePages/Happening-View.aspx?hID1/426.
5. Macklin R, Cowan E. Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Health Affairs 2012; 7:1537-1544.
6. Abdool Karim SS. An AIDS-Free Generation? Science 2012; 337:133.
7. Brock DW, Wikler D. Ethical challenges in long-term funding for HIV/AIDS. Health Affairs 2009; 28:1666-1676.
8. AbdoolKarim Q, AbdoolKarim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
9. Cohen MS. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
10. UNCommittee on Economic, Social and Cultural Rights.General Comment No. 3: The Nature of States Parties' Obligations (Art. 2, Para. 1, of the Covenant), 14 December 1990, E/1991/23, avail able at: http://www.unhcr.org/refworld/ docid/4538838e10.html [Accessed 1 June 2012].
11. Singh JA, Govender M, Mills E. Do human rights matter to health? Lancet 2007; 370:521-526.
12. International Covenant on Economic, Social and Cultural Rights. Adopted and opened for signature, ratification and accession by General Assembly resolution 2200A (XXI) of 16 December 1966; entry into force 3 January 1976, in accordance with article 27. http://www2.ohchr.org/english/law/cescr.htm.